Sanofi investigated over epilepsy drug linked to birth defects
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Sanofi (SNY) Reports Q4 Revenues of EUR9.61B
February 6, 2020 8:05 AM ESTSanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.34. Revenue for the quarter came in at EUR9.61 billion.
Sanofi Chief Executive Officer, Paul Hudson, commented:
"I am encouraged by the fourth quarter results which position Sanofi to deliver on our new strategic priorities.... More
